



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of : **Confirmation No. 2307**
Mami OJIMA et al. : Docket No. 2002_0041A
Serial No. 10/031,398 : Group Art Unit 1626
Filed January 18, 2002 : Examiner Fiona Powers

AGENT FOR PREVENTING RECURRENCE OF
CEREBROVASCULAR DISORDER AND AGENT
FOR AMELIORATING TROUBLES FOLLOWING
CEREBROVASCULAR DISORDER AND INHIBITING
PROGRESS THEREOF

RESPONSE

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

This is responsive to the Official Action dated December 22, 2003.

The Official Action constitutes a requirement for restriction.

Applicants elect to prosecute the invention of Group II, with traverse.

The compound of claim 25 (Candesartan cilexetil) is elected as the species.

The restriction requirement is untenable. The independent claims are claims 14 and 15 directed to methods of using the compounds described in the present application having angiotensin II antagonistic activity.

The following groups form a single inventive concept.

Claim 22, 23 (in part), 24-26 <Group I-IV>

Claim 34, 35 (in part), 36-38 <Group VI-IX>

Because each compound of claims 24-25 (36-38) are included in the general formula of claim 22 (34), and they have common structural feature.

Favorable reconsideration and withdrawal of the restriction requirement is respectfully solicited.

Respectfully submitted,

Mami OJIMA et al.

By: Warren M. Cheek, Jr.
Warren M. Cheek, Jr.
Registration No. 33,367
Attorney for Applicants

WMC/dlk
Washington, D.C. 20006-1021
Telephone (202) 721-8200
Facsimile (202) 721-8250
January 22, 2004